Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
2003 1
2005 2
2006 1
2008 1
2009 3
2010 2
2011 5
2012 4
2013 2
2014 3
2015 1
2016 1
2017 1
2018 1
2019 1
2020 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic activity of Sindbis virus in human oral squamous carcinoma cells.
Saito K, Uzawa K, Kasamatsu A, Shinozuka K, Sakuma K, Yamatoji M, Shiiba M, Shino Y, Shirasawa H, Tanzawa H. Saito K, et al. Br J Cancer. 2009 Aug 18;101(4):684-90. doi: 10.1038/sj.bjc.6605209. Epub 2009 Jul 28. Br J Cancer. 2009. PMID: 19638980 Free PMC article.
BACKGROUND: Sindbis virus (SIN) infection causes no or only mild symptoms (fever, rash, and arthralgia) in humans. However, SIN has a strong cytopathic effect (CPE) on various cancer cells. This study focuses on the oncolytic activity of SIN AR399 on oral can …
BACKGROUND: Sindbis virus (SIN) infection causes no or only mild symptoms (fever, rash, and arthralgia) in humans. However, SI …
Tissue-specific attenuation of oncolytic sindbis virus without compromised genetic stability.
Kueberuwa G, Cawood R, Tedcastle A, Seymour LW. Kueberuwa G, et al. Hum Gene Ther Methods. 2014 Apr;25(2):154-65. doi: 10.1089/hgtb.2013.202. Hum Gene Ther Methods. 2014. PMID: 24568203
Wild-type Sindbis virus (SV) shows promise as an oncolytic agent, although potential off-target replication is a safety concern. To remove possible pathology reflecting virus replication in liver, muscle, and/or hematopoietic cells, microRNA (miR)-resp …
Wild-type Sindbis virus (SV) shows promise as an oncolytic agent, although potential off-target replication is a safety …
Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors.
Scherwitzl I, Opp S, Hurtado AM, Pampeno C, Loomis C, Kannan K, Yu M, Meruelo D. Scherwitzl I, et al. Mol Ther Oncolytics. 2020 May 6;17:431-447. doi: 10.1016/j.omto.2020.04.012. eCollection 2020 Jun 26. Mol Ther Oncolytics. 2020. PMID: 32478167 Free PMC article.
We have developed a practical and improved strategy for cancer immunotherapy using an oncolytic virus and anti-OX40. This strategy takes advantage of a preexisting T cell immune repertoire in vivo, removing the need to know about present tumor antigens. We have show …
We have developed a practical and improved strategy for cancer immunotherapy using an oncolytic virus and anti-OX40. This stra …
Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.
Huang PY, Guo JH, Hwang LH. Huang PY, et al. Mol Ther. 2012 Feb;20(2):298-305. doi: 10.1038/mt.2011.245. Epub 2011 Nov 8. Mol Ther. 2012. PMID: 22068428 Free PMC article.
Sindbis virus (SBV) has been shown to possess oncolytic potential in many human xenograft tumor models in immunocompromised mice. ...
Sindbis virus (SBV) has been shown to possess oncolytic potential in many human xenograft tumor models in immunocomprom
Oncolytic Alphaviruses in Cancer Immunotherapy.
Lundstrom K. Lundstrom K. Vaccines (Basel). 2017 Apr 12;5(2):9. doi: 10.3390/vaccines5020009. Vaccines (Basel). 2017. PMID: 28417936 Free PMC article. Review.
In parallel to oncolytic viral vectors based on adenoviruses and herpes simplex viruses, oncolytic RNA viruses and particularly alphaviruses have been evaluated as delivery vehicles. Immunization studies in experimental rodent models for various cancers including gl …
In parallel to oncolytic viral vectors based on adenoviruses and herpes simplex viruses, oncolytic RNA viruses and particularl …
Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain.
Takenouchi A, Saito K, Saito E, Saito T, Hishiki T, Matsunaga T, Isegawa N, Yoshida H, Ohnuma N, Shirasawa H. Takenouchi A, et al. Pediatr Surg Int. 2015 Dec;31(12):1151-9. doi: 10.1007/s00383-015-3784-y. Epub 2015 Aug 23. Pediatr Surg Int. 2015. PMID: 26298056
PURPOSE: With current treatment regimens, high-risk neuroblastoma (NB) remains largely incurable. Oncolytic viral therapy uses replication-competent viruses, like Sindbis virus (SINV), to kill cancers. ...CONCLUSION: Our results suggested that SINV AR339 was …
PURPOSE: With current treatment regimens, high-risk neuroblastoma (NB) remains largely incurable. Oncolytic viral therapy uses replic …
Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain.
Unno Y, Shino Y, Kondo F, Igarashi N, Wang G, Shimura R, Yamaguchi T, Asano T, Saisho H, Sekiya S, Shirasawa H. Unno Y, et al. Clin Cancer Res. 2005 Jun 15;11(12):4553-60. doi: 10.1158/1078-0432.CCR-04-2610. Clin Cancer Res. 2005. PMID: 15958641
PURPOSE: Recently, the application of replication-competent viruses has been studied as anticancer agents. Sindbis virus (SIN) is an RNA virus that belongs to the Alphavirus genus in the Togaviridae virus family. ...RESULTS: SIN infection was able to i …
PURPOSE: Recently, the application of replication-competent viruses has been studied as anticancer agents. Sindbis virus (SIN) …
Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
Saito K, Shirasawa H, Isegawa N, Shiiba M, Uzawa K, Tanzawa H. Saito K, et al. Oral Oncol. 2009 Dec;45(12):1021-7. doi: 10.1016/j.oraloncology.2009.09.002. Epub 2009 Oct 14. Oral Oncol. 2009. PMID: 19833547 Review.
Clinical trials of oncolytic viruses show that most oncolytic agents are well tolerated and safe. ...We discuss current issues and perspectives of this evolving anticancer therapy, highlighting the potential applications of a unique, naturally occurring oncolytic
Clinical trials of oncolytic viruses show that most oncolytic agents are well tolerated and safe. ...We discuss current issues …
Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity.
Scherwitzl I, Hurtado A, Pierce CM, Vogt S, Pampeno C, Meruelo D. Scherwitzl I, et al. Mol Ther Oncolytics. 2018 May 3;9:51-63. doi: 10.1016/j.omto.2018.04.004. eCollection 2018 Jun 29. Mol Ther Oncolytics. 2018. PMID: 29988525 Free PMC article.
Oncolytic viruses represent a promising form of cancer immunotherapy. We investigated the potential of Sindbis virus (SV) for the treatment of solid tumors expressing the human cancer testis antigen NYESO-1. ...
Oncolytic viruses represent a promising form of cancer immunotherapy. We investigated the potential of Sindbis virus (S
Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells.
Bergman I, Whitaker-Dowling P, Gao Y, Griffin JA, Watkins SC. Bergman I, et al. Virology. 2003 Nov 25;316(2):337-47. doi: 10.1016/j.virol.2003.07.010. Virology. 2003. PMID: 14644615 Free article.
Vesicular stomatitis virus (VSV) is a candidate for development for cancer therapy. It is an oncolytic virus that is safe in humans. ...Analysis of the protein composition of the pseudotype VSV found low expression of the modified Sindbis gp on the …
Vesicular stomatitis virus (VSV) is a candidate for development for cancer therapy. It is an oncolytic virus that is sa …
30 results